Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
- Authors
- Lee, Young-Sun; Jun, Hee-Sook
- Issue Date
- Mar-2016
- Publisher
- HINDAWI LTD
- Citation
- MEDIATORS OF INFLAMMATION, v.2016
- Journal Title
- MEDIATORS OF INFLAMMATION
- Volume
- 2016
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/9659
- DOI
- 10.1155/2016/3094642
- ISSN
- 0962-9351
- Abstract
- Glucagon-like peptide-1 (GLP-1) is an incretin hormone mainly secreted from intestinal L cells in response to nutrient ingestion. GLP-1 has beneficial effects for glucose homeostasis by stimulating insulin secretion from pancreatic beta-cells, delaying gastric emptying, decreasing plasma glucagon, reducing food intake, and stimulating glucose disposal. Therefore, GLP-1-based therapies such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4, which is a GLP-1 inactivating enzyme, have been developed for treatment of type 2 diabetes. In addition to glucose-lowering effects, emerging data suggests that GLP-1-based therapies also showanti-inflammatory effects in chronic inflammatory diseases including type 1 and 2 diabetes, atherosclerosis, neurodegenerative disorders, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, and psoriasis. This review outlines the anti-inflammatory actions of GLP-1-based therapies on diseases associated with chronic inflammation in vivo and in vitro, and their molecular mechanisms of anti-inflammatory action.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 약학대학 > 약학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/9659)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.